NCT06028737View on ClinicalTrials.gov

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

April 25, 2027

Study Completion Date

December 31, 2032

Conditions
Gastric CancerStomach CancerGastroEsophageal CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaAdvanced Gastric AdenocarcinomaGastric NeoplasmStomach NeoplasmGastrointestinal CancerAdvanced Gastroesophageal Junction AdenocarcinomaAdvanced Gastric CarcinomaChemotherapyGastrectomyGastrectomy for Gastric CancerGastric ResectionGastric (Cardia, Body) Cancer
Interventions
DRUG

Docetaxel

50mg/m2, d1, i.v., every 2 weeks

DRUG

Oxaliplatin

85 mg/m², d1, i.v., every 2 weeks

DRUG

Leucovorin

200 mg/m², d1, i.v., every 2 weeks

DRUG

Fluorouracil

2600 mg/m²d1 i.v. every 2 weeks

Trial Locations (2)

08406

RECRUITING

National Cancer Institute, Vilnius

03022

RECRUITING

National Cancer Institute, Kyiv

All Listed Sponsors
lead

Ukrainian Society of Clinical Oncology

OTHER

NCT06028737 - Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | Biotech Hunter | Biotech Hunter